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Inverse association between soy 
food consumption, especially 
fermented soy products intake and 
soy isoflavone, and arterial stiffness 
in Japanese men
Hirokazu Uemura1, Sakurako Katsuura-Kamano1, Mariko Nakamoto2, Miwa Yamaguchi1, 
Miho Fujioka1, Yuki Iwasaki1 & Kokichi Arisawa1
Studies on the associations between soy food consumption and arterial stiffness are rare. The aim 
of the present study was to evaluate their associations in Japanese men. A total of 652 eligible men, 
aged 35–69 years, who underwent the measurement of brachial-ankle pulse wave velocity (baPWV) 
as an index of arterial stiffness were evaluated in this cross-sectional study. Information on their 
lifestyle characteristics, including dietary behavior, was obtained from a structured self-administered 
questionnaire. The frequency of total soy products as well as fermented and non-fermented soy 
products intakes was calculated, and the amounts of soy protein and soy isoflavone intakes were 
also estimated; these were then divided into tertiles and their associations with baPWV values were 
evaluated using general linear models. Higher frequency of fermented soy products intake was 
associated with decreased baPWV after adjusting for the multivariable covariates (P value for trend was 
0.002, in Model 3). This association did not alter after further adjustment with a biomarker of systemic 
inflammation (serum high-sensitivity C-reactive protein (hs-CRP)) (P value for trend was 0.001, in Model 
4). Total soy isoflavone consumption was also inversely associated with baPWV even after adjusting for 
multivariable covariates including serum hs-CRP (P value for trend was 0.043, in Model 4); however total 
soy protein consumption was not. These results demonstrated that greater consumption of soy food, 
especially fermented soy products and soy isoflavone was associated with reduced arterial stiffness, 
independent of systemic inflammation, in Japanese men.
Since cardiovascular diseases are major causes of death in developed countries, early detection of cardiovascular 
damage is desired earnestly to prevent mortality and morbidity from cardiovascular diseases. Atherosclerotic 
changes in arteries mainly contribute to the pathogenesis of cardiovascular diseases, and increased arterial stiff-
ness is demonstrated to be closely associated with atherosclerosis. Arterial stiffness can be evaluated by measuring 
arterial pulse wave velocity (PWV). Brachial-ankle PWV (baPWV) measurement is convenient, relatively quick, 
and reproducible. Moreover, baPWV value correlates well with the carotid-femoral PWV, which is an established 
index for assessing aortic stiffness1. Therefore, baPWV measurement has become popular in screening for arterial 
stiffness in Asian countries.
Isoflavone is a chemical compound that is structurally and biologically similar to estrogen2, and is known to 
have cardiovascular benefits. Dietary isoflavone is available through soybean and soy products. Soybean belongs 
to the legume family and is recognized as one of the plant foods. Soybeans have been a major component of the 
traditional Asian (including Japanese) diets, and are usually consumed as processed foods (tofu, natto, miso, 
shoyu, etc.). Fermented soy products such as miso and natto are often consumed in Japan as Japanese special 
food3. Soybean products are seen as healthy diets because of their beneficial nature of containing low fat, rich 
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protein, rich vitamins, minerals, and fiber. Due to these beneficial nature and isoflavone content, soybean and soy 
products are considered to have potential cardiovascular benefits. However, the findings of studies evaluating the 
effects of soy food or soy isoflavone intake on cardiovascular benefits have been inconsistent4–7.
The antioxidative activity of fermented soybean products has been reported to be significantly higher than that 
in non-fermented steamed soybean8,9. Such antioxidative activity receives special attention because of its potential 
beneficial effect on cardiovascular health. However, reports on the relationships between the consumption of soy 
food products, especially the consumption of fermented soy products and soy isoflavone, and arterial stiffness 
which can detect early cardiovascular damage are few. The present study evaluated the possible relationships 
between frequency of intake of the total soy products, especially fermented soy products, and arterial stiffness 
using baPWV as the parameter in Japanese men. We also evaluated the relationships between the consumption of 
soy protein and soy isoflavone and arterial stiffness.
Materials and Methods
Study subjects. This cross-sectional study included men aged 35–69 years who participated in the baseline 
survey of a prospective cohort study from November 2009 to June 2012 in Tokushima Prefecture, Japan and who 
received a baPWV measurement at the baseline survey. The subjects were workers, and most of them were office 
workers and not shift workers. This study was performed as part of the Japan Multi-Institutional Collaborative 
Cohort (J-MICC) Study, a prospective cohort study. Details of this cohort study have been reported elsewhere10. 
Briefly, the J-MICC Study aims to examine the relationships of lifestyle and genetic factors as well as their inter-
actions with lifestyle-related diseases.
All the participants in the J-MICC Study provided written informed consent prior to participation. The com-
mittees of Nagoya University School of Medicine, Aichi Cancer Center, and Tokushima University Graduate 
School approved the study protocol. This study was conducted according to the principles of the Declaration of 
Helsinki, and all methods were performed in accordance with the relevant guidelines and regulations.
Questionnaire and evaluation for soy product consumption. Information on individual medical 
histories and lifestyle characteristics, including dietary behavior over the past year, was obtained through a struc-
tured self-administered questionnaire. All the responses were reviewed by trained staff at the time of the survey. 
Leisure-time exercise was estimated on the basis of the International Physical Activity Questionnaire11. Exercise 
was divided into three levels as follows: light (e.g., walking and hiking), moderate (e.g., light jogging and swim-
ming), and vigorous (e.g., marathon running and competitive sports). The degrees of leisure-time exercise for the 
three levels were expressed as metabolic equivalent (MET)-hours/week (MET level × hours of activity × events 
per week) and summed. In this estimation, light, moderate, and vigorous exercises were assigned with 3.4, 7.0, 
and 10.0 METs, respectively.
Evaluation for soy product consumption. Diet assessment was performed using a validated short 
food frequency questionnaire (FFQ) in the baseline survey of the J-MICC Study12–15. This FFQ included ques-
tions about the intake of 47 varieties of foods and beverages over the past year. This included questions about 
the intake of four groups of soy products: (Group1) miso soup; (Group2) tofu (soybean curd) for hiyayakko, 
yu-dofu; (Group3) natto and soybeans (boiled beans, etc.); and (Group4) fried tofu paste, fried bean curd, and 
thick deep-fried tofu. Eight categories of the frequency of each soy product intake were obtained as follows: 
three or more times/day (21/week), twice/day (14/week), once/day (7/week), 5–6 times/week (5.6/week), 3–4 
times/week (3.5/week), 1–2 times/week (1.4/week), 1–3 times/month (0.7/week), and never or seldom (0/week). 
The total frequency of soy products intake was calculated as the sum of the frequencies of the four soy products 
intakes. According to the National Health and Nutrition Survey 201216, Japanese population rarely consume 
soybeans compared to natto. Natto occupies the majority of intake in Group3 (natto and soybeans). Miso is 
Japanese fermented soybean paste, while natto is made from soybeans fermented with Bacillus subtilis. Hence, the 
frequency of fermented soy products intakes was calculated as the sum of the frequencies of Group1 (miso soup) 
and Group3 (natto and soybeans) intakes. The frequency of non-fermented soy products intakes was calculated 
as the sum of the frequencies of Group2 (tofu) and Group4 (fried tofu paste, fried bean curd, and thick deep-fried 
tofu) intakes.
Next, we estimated the amount of total soy protein and total soy isoflavone intakes, as previously reported17. 
Since there were no questions on the size of each soy product consumed in the FFQ, 3-day diet records were sur-
veyed four times in approximately 3 months’ intervals (in four seasons in Japan) within one year, in a group of 28 
participants. This was used to grasp the serving size of each soy product per meal in our population to estimate 
the weekly amounts of total soy protein and total soy isoflavone intakes. The portion sizes of (1) miso soup, (2) 
tofu, (3) natto, soybean, and (4) fried tofu paste, fried bean curd, and thick deep-fried tofu were 9.9 (the amount 
used as miso), 53.8, 31.7, and 19.5 (g/meal), respectively. The amount of total soy protein intake was estimated 
by summing the soy protein contained in each specific soy food on the basis of the Standard Tables of Food 
Composition in Japan 201018. The amount of the total soy isoflavone intake was estimated by summing the soy 
isoflavone contained in each soy food based on the estimates of the phytoestrogens in foods in Japan19.
Daily intake of total energy was estimated using a program developed by the Department of Public Health, 
Nagoya City University School of Medicine12,13.
Measurements. baPWV was measured using a waveform analyzer (model BP-203RPE III; Colin, Co. Ltd., 
Komaki, Japan), as described previously20. In brief, a subject was examined while resting in the supine position in 
an air-conditioned room. Extremity blood pressure was measured using an oscillometric method, and the ankle 
brachial index (ABI) was automatically calculated. baPWV was calculated through a time-phase analysis between 
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the right brachial artery pressure and volume waveforms at both ankles. To reduce inter-observer variations, all 
baPWV measurements were performed by a single researcher throughout the duration of the study. Individual 
baPWV and ABI data were expressed as the means of the bilateral baPWV and ABI, respectively.
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Venous blood was aspi-
rated from each participant, and serum was separated within 3 hours and stored at −80 °C. Biochemical factors, 
including lipids and high-sensitivity C-reactive protein (hs-CRP) as a biomarker of systemic inflammation, in the 
stored sera, were measured at an external laboratory (BML Inc., Tokyo, Japan).
Statistical analyses. Of the 708 men initially included in this cross-sectional study, we excluded in total, 56 
men (with overlapping characteristics) as follows (shown in Fig. 1): (1) 28 men with a history of ischemic heart 
disease or stroke; (2) 5 men with a low right or left ABI (ABI ≤ 0.9), which suggested peripheral arterial occlu-
sive disease; (3) 5 men whose estimated daily total energy intake was extremely high (>4,000 kcal/day) or low 
(<1,000 kcal/day); and (4) 21 men who had no data on serum lipid or hs-CRP, frequency of soy products intakes, 
or any factors required in the multivariate models. Data on a total of 652 men were finally analyzed.
The total frequency of soy products intakes was divided into tertiles; the lowest category was used as the refer-
ence. Continuous variables were expressed as mean ± standard deviation (SD) or median values (25th percentile, 
75th percentile). Categorical variables were expressed as numbers (%). The analysis of variance, Kruskal-Wallis 
test, or chi-square test was used to compare the characteristics between the tertile categories of the total frequency 
of soy products intakes, where appropriate.
General linear models were used to evaluate the relationships of frequency of total, fermented, and 
non-fermented soy products intakes (tertiles) as well as the amount of total soy protein and total soy isoflavone 
intakes (tertiles) with baPWV after adjusting for the covariates in four model groups. In Model 1, age (con-
tinuous) and systolic blood pressure (5 categories: <120, 120 to <140, 140 to <160, or ≥160 mmHg without 
medical treatment, and use of antihypertensive agent), which are recognized as being very closely associated 
with arterial stiffness were adjusted for. In Model 2, adjustment was made for age, systolic blood pressure, BMI 
(kg/m2, quartiles), smoking habit (current or others), alcohol drinking (current or others), exercise (MET-hours/
week, quartiles), hypercholesterolemia (≥220 mg/dL or receiving medical treatment, no/yes) low high-density 
lipoprotein (HDL) cholesterol (<40 mg/dL, no/yes), elevated triglyceride levels (≥150 mg/dL, no/yes), diabetes 
(receiving medical treatment, no/yes), and daily energy intake (kcal/day, quartiles). In Model 3, the covariates 
adjusted for in Model 2 as well as coffee intake (≤1 cup/day, >1 to 3 cups/day, and >3 cups/day), calcium intake 
(mg/day, continuous, log-transformed) and total fiber intake (g/day, continuous, log-transformed) which might 
be associated with baPWV were adjusted for. Moreover, in Model 4, the covariates adjusted for in Model 3 as well 
as serum hs-CRP levels (mg/L; quartiles) were adjusted for. baPWV values and total fiber intake showed right 
skewed distributions and were included in the analyses after logarithmic transformation. Tests for trends were 
performed by assigning the ordinal variables of 1, 2, and 3 for each tertile category.
All calculations and statistical tests were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
Statistical tests were based on 2-sided probabilities, and the level of significance was set at P < 0.05.
Results
The mean age (SD) and median BMI (25th, 75th) of the study subjects were 48.8 (8.6) years and 24.2 (22.3, 26.1) 
kg/m2, respectively. The median baPWV (25th, 75th) was 1,404 (1274, 1563) cm/s.
Figure 1. A flow chart of the analyzed subjects. From 708 men who underwent the measurement of baPWV 
in the baseline survey, we finally analyzed 652 eligible men. baPWV, brachial-ankle pulse wave velocity; ABI, 
ankle-brachial pressure index.
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Characteristics of the subjects according to the frequency of total soy products and fermented soy 
products intakes. Tables 1 and 2 show the respective characteristics of the subjects according to the frequency 
of total and fermented soy products intakes. Subjects with greater frequency of total, as well as fermented soy 
products intakes showed higher degree of leisure-time exercise, higher energy intake, and greater consumption of 
calcium, total fiber, total soy protein, and total soy isoflavone, and lower prevalence of current smoking. Subjects in 
the highest tertiles of total as well as fermented soy products intakes showed the highest mean ages. baPWV values 
were marginal-significantly different between the tertiles of the frequency of fermented soy products intake (P 
value was 0.080), and these values gradually decreased as the frequency of fermented soy products intake increased.
Relationships between the frequency of total, fermented, and non-fermented soy products 
intakes and arterial stiffness. Table 3 shows the adjusted associations of the frequency of total, fermented, 
and non-fermented soy products intakes with baPWV (analyzed by general linear models). Higher frequency of 
total soy products intakes was associated with decreased baPWV after adjusting for the multivariable covariates 
including coffee, calcium, and total fiber intake (P value for trend was 0.005, in Model 3). This association did not 
alter after further adjustment with serum hs-CRP (P value for trend remained 0.005, in Model 4).
Further analyses categorizing soy products into fermented or not fermented, revealed that the frequency of 
fermented soy products intakes was inversely associated with baPWV after adjusting for multivariable covariates 
including serum hs-CRP (P value for trend was 0.001, in Model 4). However, the frequency of non-fermented soy 
products intakes was not associated with baPWV.
Relationships of total soy protein and total soy isoflavone consumption with arterial stiffness. 
As shown in Table 4, total soy isoflavone consumption was inversely associated with baPWV even after adjusting 
for multivariable covariates including serum hs-CRP (P value for trend was 0.043, in Model 4). In contrast, the 
inverse association between total soy protein consumption and baPWV attenuated, becoming non-significant 
when adjusting for coffee, calcium, and total fiber intake (Model 3), or additionally, serum hs-CRP (Model 4).
Frequency of total soy products intake (times/week)
PT1 (≤4.9) T2 (>4.9 to 8.4) T3 (>8.4)
Number (%) 232 (35.6) 203 (31.1) 217 (33.3)
Age (years)a 47.0 ± 8.4 48.8 ± 8.7 50.7 ± 8.4 <0.001
Body mass index (kg/m2)b 24.1 (22.4, 26.0) 24.6 (22.2, 26.7) 23.9 (22.1, 25.4) 0.068
Current smoking, n (%)
   No 135 (58.2) 136 (67.0) 157 (72.4) 0.006
   Yes 97 (41.8) 67 (33.0) 60 (27.6)
Current alcohol drinking, n (%)
   No 53 (22.8) 61 (30.0) 57 (26.3) 0.234
   Yes 179 (77.2) 142 (70.0) 160 (73.7)
Exercise (MET-hours/week)b 2.80 (0.43, 14.53) 4.70 (0.43, 15.05) 5.25 (1.28, 15.30) 0.025
Systolic BP (mmHg)a 135.0 ± 16.5 134.5 ± 17.3 134.7 ± 15.8 0.944
Diastolic BP (mmHg)a 84.1 ± 11.6 84.3 ± 11.6 84.7 ± 10.7 0.812
Prevalence, n (%)
   Hypertension 104 (44.8) 93 (45.8) 105 (48.4) 0.740
   Hypercholesterolemia 104 (44.8) 76 (37.4) 87 (40.1) 0.280
   Low HDL cholesterol 14 (6.0) 11 (5.4) 7 (3.2) 0.357
   Elevated triglycerides 66 (28.4) 54 (26.6) 68 (31.3) 0.557
   Diabetes 7 (3.0) 10 (4.9) 13 (6.0) 0.312
Energy intake (kcal/day)b 1743 (1530, 1920) 1788 (1641, 1950) 1876 (1702, 2067) <0.001
Coffee intake (cups/day)b 1.65 (1.5, 3.5) 1.65 (1.5, 3.0) 1.65 (0.8, 3.5) 0.089
Calcium intake (mg/day)b 355 (312, 467) 414 (364, 498) 458 (387, 554) <0.001
Total fiber intake (g/day)b 7.3 (6.3, 8.6) 8.3 (7.3, 9.5) 9.9 (8.4, 11.9) <0.001
Intake frequency of total soy products (times/week)b 3.5 (2.8, 4.2) 7.0 (6.3, 7.7) 11.2 (9.8, 14.7) <0.001
Intake frequency of fermented soy products (times/week)b 2.1 (1.4, 2.8) 4.9 (4.2, 6.3) 8.4 (7.0, 10.5) <0.001
Intake frequency of non-fermented soy products (times/week)b 1.4 (0.7, 2.1) 1.4 (1.4, 2.1) 2.8 (2.1, 4.2) <0.001
Total soy protein consumption (g/week)b 8.5 (5.9, 10.9) 14.2 (11.8, 17.4) 27.8 (19.9, 38.3) <0.001
Total soy isoflavone consumption (mg/week)b 31.5 (18.7, 41.3) 55.6 (45.3, 65.3) 102.3 (78.3, 151.6) <0.001
Serum hs-CRP (mg/L)b 0.36 (0.22, 0.86) 0.37 (0.19, 0.81) 0.34 (0.18, 0.73) 0.380
ABIa 1.12 ± 0.07 1.12 ± 0.06 1.13 ± 0.06 0.118
BaPWV (cm/s)b 1429 (1272, 1574) 1399 (1281, 1581) 1404 (1251, 1540) 0.710
Table 1. Characteristics of the subjects according to the frequency of total soy products intake. aMean ± SD. 
bMedian (25%, 75%). BP, blood pressure; HDL, high density lipoprotein; hs-CRP, high-sensitivity C-reactive 
protein. ABI, ankle-brachial pressure index; baPWV, brachial-ankle pulse wave velocity.
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Discussion
The current study revealed that greater consumption of total soy products, especially fermented soy products 
and soy isoflavone, was dose-dependently associated with decreased arterial stiffness, independent of traditional 
atherosclerotic risk factors or systemic inflammation, in Japanese men.
Since cardiovascular diseases are leading causes of death in developed countries, measures against cardiovas-
cular damage is important to prevent mortality and morbidity from cardiovascular diseases. Soybean and soy 
products contain rich protein, vitamins, minerals, fiber, and isoflavone; therefore, they are paid special attention 
due to the potential cardiovascular benefits. Findings of a most recent meta-analysis concluded that soy consump-
tion was negatively associated with the risk of cardiovascular diseases, stroke, and coronary heart disease risk4. 
However, in the subgroup meta-analyses, a statistically significant protective effect of soy consumption on car-
diovascular disease risk was primarily observed in Asian populations4. In contrast, Low et al.5 in a meta-analysis 
combining cohort studies, showed no association between soy intake and the risk of stroke or coronary heart 
disease, although a significantly inverse association between soy intake and the risk of stroke and coronary heart 
disease was observed in case-control studies. Thus, currently, the conclusions for the favorable effect of soy intake 
on the risk of cardiovascular diseases have remained inconsistent.
Soybeans are usually consumed as processed foods (tofu, natto, miso, shoyu, etc.) in Japan, and fermented soy 
products such as miso and natto are Japanese special food7. Therefore, we additionally evaluated the associations 
between soy food consumption and arterial stiffness by categorizing soy food into fermented or not fermented. 
The frequency of fermented soy products intakes was inversely associated with arterial stiffness after adjusting for 
multivariable covariates, while frequency of non-fermented soy products intakes was not. In a population-based 
cohort study in Japan, natto intake was associated with the decreased risk of cardiovascular disease mortality21. 
Natto possesses strong fibrinolytic activity and anti-coagulation profiles22,23. Natto is also demonstrated to have 
favorable effect on blood pressure24. Antioxidative activity has potential beneficial effect on cardiovascular health, 
and the antioxidative activity of fermented soybean products has been reported to be significantly higher than 
that in non-fermented steamed soybean8,9. The findings of these reports lend support to the results of our study. 
Frequency of fermented soy products intake. (times/week)
PT1 (≤2.8) T2 (>2.8 to 6.3) T3 (>6.3)
Number (%) 211 (32.4) 215 (33.0) 226 (34.7)
Age (years)a 48.0 ± 8.5 47.8 ± 8.9 50.5 ± 8.3 0.001
Body mass index (kg/m2)b 24.1 (22.4, 25.9) 24.4 (22.5, 26.7) 24.0 (22.0, 25.7) 0.193
Current smoking, n (%)
   No 131 (62.1) 134 (62.3) 163 (72.1) 0.040
   Yes 80 (37.9) 81 (37.7) 63 (27.9)
Current alcohol drinking, n (%)
   No 53 (25.1) 49 (22.8) 69 (30.5) 0.165
   Yes 158 (74.9) 166 (77.2) 157 (69.5)
Exercise (MET-hours/week)b 2.98 (0.43, 15.30) 3.90 (1.28, 11.70) 5.95 (1.28, 15.30) 0.026
Systolic BP (mmHg)a 135.3 ± 16.2 134.5 ± 17.5 134.5 ± 15.7 0.868
Diastolic BP (mmHg)a 84.4 ± 11.5 84.2 ± 11.6 84.5 ± 10.8 0.973
Prevalence, n (%)
   Hypertension 98 (46.4) 96 (44.7) 108 (47.8) 0.803
   Hypercholesterolemia 99 (46.9) 73 (34.0) 95 (42.0) 0.023
   Low HDL cholesterol 12 (5.7) 11 (5.1) 9 (4.0) 0.701
   Elevated triglycerides 61 (28.9) 58 (27.0) 69 (30.5) 0.712
   Diabetes 7 (3.3) 8 (3.7) 15 (6.6) 0.192
Energy intake (kcal/day)b 1758 (1536, 1923) 1770 (1588, 1966) 1852 (1698, 2052) <0.001
Coffee intake (cups/day)b 1.65 (1.5, 3.5) 1.65 (1.5, 3.5) 1.65 (0.8, 3.5) 0.192
Calcium intake (mg/day)b 378 (318, 486) 405 (355, 479) 450 (377, 548) <0.001
Intake frequency of total soy products (times/week)b 3.5 (2.1, 4.2) 6.3 (5.6, 7.7) 11.2 (9.1, 14.7) <0.001
Intake frequency of fermented soy products (times/week)b 1.4 (1.4, 2.1) 4.9 (4.2, 5.6) 7.7 (7.0, 10.5) <0.001
Intake frequency of non-fermented soy products (times/week)b 1.4 (0.7, 2.1) 1.4 (0.7, 2.1) 2.1 (1.4, 4.2) <0.001
Total fiber intake (g/day)b 7.3 (6.3, 8.6) 8.2 (7.3, 9.5) 9.5 (8.3, 11.7) <0.001
Total soy protein consumption (g/week)b 9.3 (5.9, 12.8) 14.2 (10.4, 17.4) 24.8 (17.8, 37.9) <0.001
Total soy isoflavone consumption (mg/week)b 34.9 (18.7, 49.5) 55.0 (39.9, 67.9) 97.0 (69.0, 147.8) <0.001
Serum hs-CRP (mg/L)b 0.33 (0.20, 0.85) 0.40 (0.19, 0.86) 0.35 (0.20, 0.72) 0.718
ABIa 1.12 ± 0.07 1.12 ± 0.06 1.13 ± 0.06 0.169
BaPWV (cm/s)a 1437 (1302, 1581) 1400 (1267, 1575) 1386 (1251, 1528) 0.080
Table 2. Characteristics of the subjects according to the frequency of fermented soy products intake. 
aMean ± SD. bMedian (25%, 75%). BP, blood pressure; HDL, high density lipoprotein; hs-CRP, high-sensitivity 
C-reactive protein. ABI, ankle-brachial pressure index; baPWV, brachial-ankle pulse wave velocity.
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The present study also revealed that intake of total soy isoflavone, which has antioxidative activity, was inversely 
associated with arterial stiffness even after adjusting for multivariable covariates. When estimated total isoflavone 
consumption was used as a continuous variable (mg/week) (not by tertiles), it was also inversely correlated with 
baPWV: age-adjusted rank order correlation coefficient between total soy isoflavone consumption and baPWV 
(continuous, cm/sec) was −0.147 (P < 0.001). These results are concordant with the results in a previous systemic 
review which reported that soy isoflavone supplementation provides an effective means of reducing arterial stiff-
ness25. However, according to the previous reports in Europe, dietary isoflavone intake was not associated with 
Intake frequency (times/week)
P for 
trend
T1 T2 T3
Adjusted 
mean (95%CI)
Adjusted 
mean (95%CI)
Adjusted 
mean (95%CI)
Total soy products T1 (≤4.9) T2 (>4.9 to 8.4) T3 (>8.4)
Model 1 1494 (1469, 1518) 1469 (1444, 1493) 1436 (1412, 1460) <0.001
Model 2 1523 (1478, 1570) 1505 (1459, 1552) 1468 (1424, 1514) <0.001
Model 3 1522 (1476, 1570) 1506 (1460, 1553) 1469 (1424, 1516) 0.005
Model 4 1520 (1473, 1568) 1503 (1457, 1550) 1467 (1422, 1514) 0.005
Fermented soy 
products T1 (≤2.8) T2 (>2.8 to 6.3) T3 (>6.3)
Model 1 1495 (1470, 1521) 1474 (1450, 1499) 1432 (1409, 1456) <0.001
Model 2 1527 (1481, 1575) 1513 (1467, 1560) 1467 (1424, 1512) <0.001
Model 3 1526 (1479, 1574) 1514 (1467, 1561) 1469 (1425, 1514) 0.002
Model 4 1525 (1478, 1573) 1510 (1464, 1558) 1466 (1422, 1512) 0.001
Non-fermented 
soy products T1 (≤0.7) T2 (>0.7 to 2.1) T3 (>2.1)
Model 1 1478 (1450, 1508) 1459 (1438, 1479) 1471 (1444, 1499) 0.755
Model 2 1502 (1454, 1552) 1494 (1451, 1539) 1506 (1459, 1554) 0.820
Model 3 1496 (1448, 1546) 1494 (1450, 1538) 1512 (1465, 1561) 0.402
Model 4 1493 (1445, 1543) 1491 (1448, 1536) 1510 (1462, 1559) 0.396
Table 3. Associations of the frequency of total, fermented, and non-fermented soy products intakes with 
baPWV. baPWV, brachial-ankle pulse wave velocity; T1, first tertile; T2, second tertile; T3, third tertile; CI, 
confidence interval. Model 1: adjusted for age and systolic blood pressure. Model 2: adjusted for age, systolic 
blood pressure, body mass index, smoking habit, alcohol drinking, exercise, hypercholesterolemia, low high-
density lipoprotein cholesterol, elevated triglyceride levels, diabetes, and daily energy intake. Model 3: adjusted 
for the covariates in model 2 plus coffee intake, calcium intake, and total fiber intake. Model 4: adjusted for 
the covariates in model 3 plus serum hs-CRP levels. baPWV values were log-transformed before analyses, and 
geometric adjusted means and their 95% CIs are presented.
Estimated intake amount
P for 
trend
T1 T2 T3
Adjusted 
mean (95%CI)
Adjusted 
mean (95%CI)
Adjusted 
mean (95%CI)
Total soy protein (g/week) T1 (≤11.4) T2 (>11.4 to 18.5) T3 (>18.5)
Model 1 1492 (1467, 1517) 1459 (1435, 1484) 1447 (1422, 1471) 0.005
Model 2 1521 (1475, 1569) 1495 (1450, 1541) 1480 (1435, 1526) 0.016
Model 3 1518 (1470, 1566) 1495 (1450, 1542) 1484 (1438, 1532) 0.092
Model 4 1514 (1467, 1563) 1493 (1448, 1540) 1482 (1436, 1530) 0.112
Total soy isoflavone (mg/week) T1 (≤41.5) T2 (>41.5 to 70.2) T3 (>70.2)
Model 1 1495 (1470, 1520) 1458 (1434, 1483) 1445 (1420, 1469) 0.002
Model 2 1525 (1479, 1573) 1493 (1448, 1539) 1478 (1433, 1525) 0.006
Model 3 1523 (1475, 1571) 1493 (1448, 1539) 1481 (1435, 1529) 0.037
Model 4 1519 (1472, 1568) 1491 (1446, 1537) 1479 (1433, 1527) 0.043
Table 4. Associations of the estimated intake amount of total soy protein and total soy isoflavone with baPWV. 
baPWV, brachial-ankle pulse wave velocity; T1, first tertile; T2, second tertile; T3, third tertile; CI, confidence 
interval. Model 1: adjusted for age and systolic blood pressure. Model 2: adjusted for age, systolic blood pressure, 
body mass index, smoking habit, alcohol drinking, exercise, hypercholesterolemia, low high-density lipoprotein 
cholesterol, elevated triglyceride levels, diabetes, and daily energy intake. Model 3: adjusted for the covariates in 
model 2 plus coffee intake, calcium intake, and total fiber intake. Model 4: adjusted for the covariates in model 3 
plus serum hs-CRP levels. baPWV values were log-transformed before analyses, and geometric adjusted means 
and their 95% CIs are presented.
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cardiovascular disease risk in Dutch women6 or with cardiovascular disease mortality in Spanish adults7. Low et 
al.5 also reported in their meta-analysis that no association between soy isoflavone intake and the risk of stroke 
and coronary heart disease was identified. Currently, as similar to the effect of soy food intake, the effect of soy 
isoflavone intake on the cardiovascular risk have remained inconsistent. Possible explanations for these incon-
sistencies include the differences in study designs, different amounts of soy intake in target populations, and dif-
ferent types of consumed soy products. The amount of soy consumption, especially intake amounts of fermented 
soy products, is higher in Asian populations than in Western populations26. In addition, the prevalence of equol 
producer is higher in Asian populations (about 50–60%)27 than in Western populations (about 20–30%)28. Equol 
is a metabolite of the dietary isoflavone produced by the action of intestinal bacteria in response to soy isoflavone 
intake27. Equol has selective affinity for the estrogen receptor β, that is also expressed in the vasculature. Equol 
possesses a longer half-life and higher bioavailability than genistein and daidzein, being the major isoflavones in 
soybean, and equol has been suggested to have the highest antioxidant properties of the isoflavones27,29. Recently, 
equol producer status has been reported to be inversely associated with arterial stiffness in Japanese women 
around menopause and early postmenopause30 and coronary calcification in Japanese men31. Equol supplemen-
tation has also been reported to decrease arterial stiffness in men32 and women33. Then, equol may have greater 
anti-atherosclerotic properties than other isoflavones. Because fermented soy products can skip the initial steps 
of soy metabolism in the intestine, they may contribute to larger production of equol than non-fermented soy 
food. Further studies determining equol-producing abilities of the individuals will be needed to determine the 
relationships between soy isoflavone consumption and cardiovascular health.
Coffee is often consumed worldwide including Japan. Coffee contains rich antioxidants such as chlorogenic 
acid and other bioactive compounds34. Epidemiologic studies have demonstrated inverse associations between 
coffee intake and diabetes35 and metabolic syndrome36,37, which are high risk conditions for atherosclerosis. A 
previous study conducted by us demonstrated that coffee consumption was inversely associated with arterial 
stiffness in Japanese men38. Dietary calcium is also suggested to be inversely associated with cardiovascular risk 
and mortality39,40; however, excessive calcium intake via supplementation may have adverse influence on vascular 
events41. Calcium is considered to be involved in the regulation of vascular smooth muscle cell contractility42 and 
reducing platelet aggregation43. Sufficient dietary fiber intake is also demonstrated to be associated with a reduced 
risk of cardiovascular disease through its impact on the glycemic response44,45. Soybean products contain rich 
calcium and fiber. Therefore, we additionally adjusted for coffee intake, calcium intake, and total fiber intake, 
which may be associated with arterial stiffness in the analyses. The inverse associations between the frequency of 
fermented soy products intakes as well as soy isoflavone consumption and arterial stiffness were slightly attenu-
ated but remained significant, although the association between soy protein consumption and arterial stiffness 
became non-significant. This finding suggests that fermented soy products as well as soy isoflavone intake may be 
associated with reduced arterial stiffness. This association may be slightly dependent on intakes of coffee as well as 
calcium and fiber which are rich in soy products, however, other independent mechanisms may exist.
Chronic systemic inflammation has been recognized as a key player in the pathogenesis of various diseases 
including cardiovascular disease46,47. Hs-CRP is a sensitive biomarker of systemic inflammation48, and hs-CRP 
measurement in blood has recently become popular in clinical and health examination settings for assessing 
low-grade systemic inflammation. After further adjusting for serum hs-CRP levels (Model 4), the inverse associa-
tions between the frequency of fermented soy products intakes as well as soy isoflavone consumption and arterial 
stiffness did not alter. Therefore, the observed associations with arterial stiffness might be independent of chronic 
systemic inflammation.
The present study has several limitations. First, because of the cross-sectional study design, causal rela-
tionships between soy products and soy isoflavone consumption and reduced arterial stiffness could not be 
established. Second, information about the frequency of soy products intakes was self-reported; therefore, 
non-differential misclassification might have been inevitable. Moreover, we could not obtain information on 
the size of the consumed foods. Hence, we calculated the intake of soy products per meal from a four, 3-day diet 
records of 28 participants, in order to estimate soy protein and isoflavone consumption. Correlation coefficients 
between the estimated consumptions of soy protein and isoflavone from the FFQs and the diet records were 0.47 
and 0.59 (Spearman’s rank correlation), respectively17. Additionally, the amounts of soy protein and soy isoflavone 
intakes as well as the total energy intake may be underestimated due to our short FFQ; however, their ranking 
might be satisfactory. Third, we did not determine the equol-producing abilities of the subjects. Fourth, although 
we adjusted for a number of potential confounding factors in the analyses, residual confounding could not be 
eliminated. Fourth, our study included a relatively small number of subjects. Finally, because all of our subjects 
were Japanese men, the results may not be generalizable to women or to other ethnic populations.
In conclusion, our study demonstrated that greater consumption of soy products, especially fermented soy 
products, as well as soy isoflavone was associated with reduced arterial stiffness, independent of the classical 
atherosclerotic risk factors and of chronic systemic inflammation, in Japanese men. Prospective or interventional 
studies that additionally include women are required to confirm our findings.
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